On Sept. 22, 2020, Codagenix announced that the Serum Institute of India has begun manufacturing CDX-005, the company’s intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.

Codagenix collaborated with the Serum Institute of India to develop CDX-005. Preclinical animal studies were successfully completed, and Codagenix expected to initiate a Phase 1 first-in-human clinical trial in the UK by the end of 2020.

Having received the necessary regulatory approval from the Review Committee on Genetic Manipulation (RCGM) of India’s Department of Biotechnology (DBT), Serum Institute will initiate manufacturing for large-scale safety and efficacy studies, in addition to preparing to meet global vaccine supply requirements.